Inhibition of prostaglandin induced uterine activity in the second trimester of pregnancy by beta-mimetic adrenergic agents.
D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000605:Amino Alcohols / Q000008:administration & dosage / Q000494:pharmacology; D000649:Amniocentesis; D000653:Amniotic Fluid; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007267:Injections; D007275:Injections, Intravenous; D009921:Metaproterenol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D009119:Muscle Contraction / Q000187:drug effects*; D010627:Phenethylamines / Q000008:administration & dosage / Q000494:pharmacology*; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology; D011247:Pregnancy; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000008:administration & dosage / Q000494:pharmacology*; D011674:Pulse / Q000187:drug effects; D013268:Stimulation, Chemical; D013997:Time Factors; D014599:Uterus / Q000187:drug effects*
D000318:Adrenergic beta-Agonists; D000605:Amino Alcohols; D010627:Phenethylamines; D010636:Phenols; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D009921:Metaproterenol